Fisetin and Quercetin Show Real Promise as Natural Senolytic Compounds
A 2026 review evaluates how two common dietary flavonoids target senescent cells, potentially slowing aging and age-related disease.
Summary
This narrative review examines the senotherapeutic potential of two dietary polyphenols — fisetin and quercetin — in combating cellular senescence, a key driver of aging and age-related diseases. Analyzing 18 animal studies and multiple human interventional trials, the authors find both compounds can reduce senescent cell burden and suppress the senescence-associated secretory phenotype (SASP). Fisetin showed consistent reductions in p16INK4a, p21Cip1, and SA-β-gal markers across aging mouse models. Quercetin, often combined with dasatinib, demonstrated broader senolytic range. Human trials showed encouraging but variable results. Key barriers to clinical translation include poor bioavailability, inconsistent dosing, and limited standardized biomarker panels for senescence in humans.
Detailed Summary
Cellular senescence — the state in which damaged cells stop dividing but resist death and secrete pro-inflammatory molecules (SASP) — is now recognized as a central hallmark of aging and a driver of conditions ranging from cardiovascular disease to neurodegeneration. This 2026 narrative review from Maastricht University investigates whether two widely available dietary flavonoids, fisetin and quercetin, can serve as practical senotherapeutics by either selectively eliminating senescent cells (senolytics) or dampening their harmful secretions (senomorphics).
The authors reviewed 18 animal studies: six testing fisetin alone and twelve testing quercetin predominantly in combination with the kinase inhibitor dasatinib (Q+D). Most studies used naturally aging or progeroid mouse models (C57BL/6, SAMP10, Ercc1−/Δ), with one notable sheep study offering stronger translational relevance. Fisetin (50–100 mg/kg, oral or IV) consistently reduced SA-β-gal+ cells, p16INK4a, and p21Cip1 expression across multiple tissues. It also suppressed key SASP factors including IL-6, IL-1β, TNF-α, and MCP-1, and improved physical function metrics such as grip strength and locomotor activity in aged mice. The Q+D combination produced comparable or superior senolytic effects, clearing senescent cells across adipose, liver, lung, and kidney tissues while extending median lifespan in progeroid models.
In human interventional trials, the evidence is more limited but still suggestive. The landmark Mayo Clinic trial (MKT-231) found that a short course of Q+D reduced senescent cell burden in adipose tissue of diabetic kidney disease patients, as measured by p16INK4a and p21Cip1 expression, and improved physical function. A pilot trial of fisetin in older adults (AFFIRM-LITE) reported reductions in several SASP-related plasma proteins including MMP-3, MMP-12, and CXCL9, though primary endpoints were not met. Additional small trials in patients with frailty, Alzheimer's disease risk, and COVID-19 long-haulers provide preliminary signals of benefit.
Mechanistically, both polyphenols target overlapping pathways: inhibition of Bcl-2 anti-apoptotic proteins (driving senescent cell death), suppression of PI3K/AKT/mTOR signaling (reducing SASP maintenance), and downregulation of NF-κB (dampening inflammatory output). Fisetin additionally activates SIRT1-mediated deacetylation pathways linked to longevity. Quercetin also inhibits serpins and ephrin signaling, expanding its senolytic target range.
The review highlights important translational barriers. Bioavailability of both compounds is poor and highly variable due to gut metabolism; liposomal and nanoparticle delivery systems are being explored as solutions. Human dosing regimens remain unstandardized, and no validated blood-based senescence biomarker panel yet exists for clinical use. The authors advocate for intermittent 'hit-and-run' dosing strategies consistent with senolytic mechanisms, and call for larger, well-powered RCTs with pre-specified biomarker endpoints to confirm efficacy and safety in aging human populations.
Key Findings
- Fisetin reduced p16INK4a, p21Cip1, and SA-β-gal+ cells across multiple tissues in aging and progeroid mouse models.
- Quercetin plus dasatinib extended median lifespan and reduced SC burden in progeroid mice across multiple organ systems.
- Human pilot trials of fisetin and Q+D showed reductions in senescence and SASP biomarkers in adipose tissue and plasma.
- Both compounds suppress NF-κB, PI3K/AKT/mTOR, and Bcl-2 pathways — key drivers of senescent cell survival and SASP.
- Poor bioavailability and lack of standardized human senescence biomarkers remain the primary barriers to clinical translation.
Methodology
This is a narrative literature review covering 18 animal studies and multiple human interventional trials assessing fisetin and quercetin as senotherapeutics. Animal models included naturally aging C57BL/6 mice, progeroid SAMP10 and Ercc1−/Δ mice, and one sheep study. Human studies included small pilot RCTs and open-label trials in populations with diabetes, frailty, kidney disease, and Alzheimer's disease risk.
Study Limitations
The review is narrative rather than systematic, limiting reproducibility and introducing selection bias. Human trial sample sizes are small and results are inconsistent, with some primary endpoints unmet. Bioavailability variability and the absence of validated human senescence biomarker panels make cross-study comparisons difficult.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.